The use of laboratory methods in differential diagnosis and treatment of SLE and antiphospholipid syndrome

Expert Review of Clinical Immunology

Volumn 3, Issue 4, 2007, Pages 613-622

  Alba, Paula ^a   Bertolaccini, Maria Laura ^b   Khamashta, Munther A ^b  

^a UNIVERSIDAD NACIONAL DE CÓRDOBA   (Argentina)

^b ST THOMAS HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ABETIMUS; ANTINUCLEAR ANTIBODY; AUTOANTIBODY; BETA2 GLYCOPROTEIN 1 ANTIBODY; CARDIOLIPIN ANTIBODY; COMPLEMENT COMPONENT C1Q ANTIBODY; DOUBLE STRANDED DNA; DOUBLE STRANDED DNA ANTIBODY; LA ANTIBODY; LUPUS ANTICOAGULANT; NUCLEOSOME ANTIBODY; PHOSPHOLIPID ANTIBODY; PLACEBO; PREDNISONE; PROTHROMBIN ANTIBODY; RIBONUCLEOPROTEIN ANTIBODY; RO ANTIBODY; SM ANTIBODY;

ANTIPHOSPHOLIPID SYNDROME; CLINICAL TRIAL; DIAGNOSTIC VALUE; DIFFERENTIAL DIAGNOSIS; DISEASE ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; IMMUNOASSAY; IMMUNODIFFUSION; LABORATORY TEST; RADIOIMMUNOASSAY; REVIEW; SCREENING TEST; SYSTEMIC LUPUS ERYTHEMATOSUS;

EID: 34547129115     PISSN: 1744666X     EISSN: None     Source Type: Journal    
DOI: 10.1586/1744666X.3.4.613     Document Type: Review

References (113)

1. Swaak AJ, Huysen V, Nossent JC, Smeenk RJ. Antinuclear antibody profiles in relation to specific disease manifestation of systemic lupus erythematosus. Clin. Rheumatol. 9(1), 82-94 (1990).
2. Canoso RT, de Oliveira RM. Characterization and antigenic specificity of chlorpromazine-induced antinuclear antibodies. J. Lab. Clin. Med. 108(3), 213-216 (1986).
3. Sherer Y, Gorstein A, Fritzler MJ, Shoenfeld Y. Autoantibody explosion in systemic lupus erythematosus: more than 100 different antibodies found in SLE patients. Semin. Arthritis Rheum. 34(2), 501-537 (2004).
4. Lefkowith JB, Gilkeson GS. Nephritogenic autoantibodies in lupus: current concepts and continuing controversies. Arthritis Rheum. 39(6), 894-903 (1996).
5. Sthoeger ZM, Tartakovsky B, Bentwich Z, Mozes E. Monoclonal anticardiolipin antibodies derived from mice with experimental lupus erythematosus: characterization and the induction of a secondary antiphospholipid syndrome. J. Clin. Immunol. 13(2), 127-138 (1993).
6. Sheldon J. Laboratory testing in autoimmune rheumatic diseases. Best Pract. Res. Clin. Rheumatol. 18(3), 249-269 (2004).
7. Hargreaves MM, Richmond H, Morton R. Presentation of two bone marrow elements: the "Tart" cell and the "LE" cell. Mayo. Clin. Proc. 23, 25-218 (1948).
8. Holborow J, Weir DM. A serum factor in lupus erythematosus with affinity for tissue nuclei. Br. Med. J. 2, 732-734 (1957).
9. Holman HR, Kunkel HG. Affinity between the lupus erythematosus; serum factor and cell nuclei and nucleoprotein. Science126, 162-163 (1957).
10. Toolan HW. Transplantable human neoplasms maintained in cortisone-treated laboratory animals: H.S. No. 1; H.Ep. No. 1; H.Ep. No. 2; H.Ep. No. 3; and H.Emb.Rh. No. 1. Cancer Res. 14(9), 660-666 (1954).
11. Moore AE, Sabachewsky L, Toolan HW. Culture characteristics of four permanent lines of human cancer cells. Cancer Res. 15(9), 598-602 (1955).
12. Solomon DH, Kavanaugh AJ, Schur PH. Evidence-based guidelines for the use of immunologic tests: antinuclear antibody testing. Arthritis Rheum. 47(4), 434-444 (2002).
13. Emlen W, O'Neill L. Clinical significance of antinuclear antibodies: comparison of detection with immunofluorescence and enzyme-linked immunosorbent assays. Arthritis Rheum. 40(9), 1612-1618 (1997)
14. Shoenfeld Y, Isenberg DA. The mosaic of autoimmunity. Immunol. Today 10(4), 123-126 (1989).
15. Rubin RL, Bell SA, Burlingame RW. Autoantibodies associated with lupus induced by diverse drugs target a similar epitope in the (H2A-H2B)-DNA complex. J. Clin. Invest. 90(1),165-173 (1992).
16. Eriksson C, Engstrand S, Sundqvist KG, Rantapaa-Dahlqvist S. Autoantibody formation in patients with rheumatoid arthritis treated with anti-TNF α Ann. Rheum. Dis. 64(3), 403-407 (2005).
17. Arbuckle MR, McClain MT, Rubertone MV et al. Development of autoantibodies before the clinical onset of systemic lupus erythematosus. N. Engl. J. Med. 349(16), 1526-1533 (2003).
18. Worrall JG, Snaith ML, Batchelor JR, Isenberg DA. SLE: a rheumatological view. Analysis of the clinical features, serology and immunogenetics of 100 SLE patients during long-term follow-up. Q. J. Med. 74(275), 319-330 (1990).
19. Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 40(9), 1725 (1997).
20. Waldman M, Madaio MP. Pathogenic autoantibodies in lupus nephritis. Lupus 14(1), 19-24 (2005).
21. Mannik M, Merrill CE, Stamps LD, Wener MH. Multiple autoantibodies form the glomerular immune deposits in patients with systemic lupus erythematosus. J. Rheumatol. 30(7), 1495-1504 (2003).
22. Deshmukh US, Bagavant H, Fu SM. Role of anti-DNA antibodies in the pathogenesis of lupus nephritis. Autoimmun. Rev. 5(6), 414-418 (2006).
23. Kavanaugh AF, Solomon DH. Guidelines for immunologic laboratory testing in the rheumatic diseases: anti-DNA antibody tests. Arthritis Rheum. 47(5), 546-555 (2002).
24. Tan EM, Smolen JS, McDougal JS et al. A critical evaluation of enzyme immunoassay kits for detection of antinuclear autoantibodies of defined specificities. II. Potential for quantitation of antibody content. J. Rheumatol. 29(1), 68-74 (2002).
25. Fritzler MJ, Wiik A, Tan EM et al. A critical evaluation of enzyme immunoassay kits for detection of antinuclear autoantibodies of defined specificities. III. Comparative performance characteristics of academic and manufacturers' laboratories. J. Rheumatol. Int. 3(11), 2374-2381 (2003).
26. Smeenk RJ, van den Brink HG, Brinkman K, Termaat RM, Berden JH, Swaak AJ. Anti-dsDNA: choice of assay in relation to clinical value. Rheumatol. Int. 11(3), 101-107 (1991).
27. Riboldi P, Gerosa M, Moroni G et al. Anti-DNA antibodies: a diagnostic and prognostic tool for systemic lupus erythematosus? Autoimmunity 38(1), 39-45 (2005).
28. Wallace DA, Hahn BH. Dubois' Lupus Erythematosus. Lippincott Williams & Wilkins, PA, USA (2007).
29. Neogi T Gladman DD, Ibanez D, Urowitz M. Anti-dsDNA antibody testing by Farr and ELISA techniques is not equivalent J. Rheumatol. 33(9), 1785-1788 (2006).
30. ter Borg EJ, Horst G, Hummel EJ, Limburg PC, Kallenberg CG. Measurement of increases in anti-double-stranded DNA antibody levels as a predictor of disease exacerbation in systemic lupus erythematosus. A long-term, prospective study. Arthritis Rheum. 33(5), 634-643 (1990).
31. Bootsma H, Spronk R Derksen R et al. Prevention of relapses in systemic lupus erythematosus. Lancet 345 (8965), 1595-1599 (1995).
32. Linnik MD, Hu JZ, Heilbrunn KR, Strand V, Hurley FL, Joh T. Relationship between anti-double-stranded DNA antibodies and exacerbation of renal disease in patients with systemic lupus erythematosus. Arthritis Rheum. 52(4), 1129-1137 (2005).
33. Esdaile JM, Abrahamowicz M, Joseph L, MacKenzie T, Li Y, Danoff D. Laboratory tests as predictors of disease exacerbations in systemic lupus erythematosus. Why some tests fail. Arthritis Rheum. 39(3), 370-378 (1996).
34. Petri M, Genovese M, Engle E, Hochberg M. Definition, incidence, and clinical description of flare in systemic lupus erythematosus. A prospective cohort study. Arthritis Rheum. 34(8), 937-944 (1991).
35. Ho A, Magder LS, Barr SG, Petri M. Decreases in anti-double-stranded DNA levels are associated with concurrent flares in patients with systemic lupus erythematosus. Arthritis Rheum. 44(10), 2342-2349 (2001).
36. Tseng CE, Buyon JP, Kim M et al. The effect of moderate-dose corticosteroids in preventing severe flares in patients with serologically active, but clinically stable, systemic lupus erythematosus: findings of a prospective, randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 54(11), 3623-3632 (2006).
37. Yee CS, Hussein H, Skan J, Bowman S, Situnayake D, Gordon C. Association of damage with autoantibody profile, age, race, sex and disease duration in systemic lupus erythematosus. Rheumatology (Oxford) 42(2), 276-279 (2003).
38. Prasad R, Ibanez D, Gladman D, Urowitz M. Anti-dsDNA and anti-Sm antibodies do not predict damage in systemic lupus erythematosus. Lupus 15(5), 285-291 (2006).
39. Zonana-Nacach A, Barr SG, Magder LS, Petri M. Damage in systemic lupus erythematosus and its association with corticosteroids. Arthritis Rheum. 43(8), 1801-1808 (2000).
40. Schmauss C, McAllister G, Ohosone Y, Hardin JA, Lerner MR. A comparison of snRNP-associated Sm-autoantigens: human N, rat N and human B/B'. Nucleic Acids Res. 17(4), 1733-1743 (1989).
41. Rokeach LA, Haselby JA, Hoch SO. Molecular cloning of a cDNA encoding the human Sm-D autoantigen. Proc. Natl. Acad. Sci. USA 85(13), 4832-4836 (1988).
42. Hinterberger M, Pettersson I, Steitz JA. Isolation of small nuclear ribonucleoproteins containing Ul, U2, U4, U5, and U6 RNAs. J. Biol. Chem. 258(4), 2604-2613(1983).
43. Harley JB, Gaither KK. Autoantibodies. Rheum. Dis. Clin. North Am. 14(1), 43-56 (1988).
44. Benito-Garcia E, Schur PH, Lahita R. Guidelines for immunologic laboratory testing in the rheumatic diseases: anti-Sm and anti-RNP antibody tests. Arthritis Rheum. 51(6), 1030-1044 (2004).
45. McCarty GA, Harley JB, Reichlin M. A distinctive autoantibody profile in black female patients with lupus nephritis. Arthritis Rheum. 36(11), 1560-1565 (1993).
46. Thompson D, Juby A, Davis P. The clinical significance of autoantibody profiles in patients with systemic lupus erythematosus. Lupus 2(1), 15-19 (1993).
47. Munves EF, Schur PH. Antibodies to Sm and RNP. Prognosticators of disease involvement. Arthritis Rheum. 26(7), 848-853 (1983).
48. Alba P, Bento L, Cuadrado MJ et al. Anti-dsDNA, anti-Sm antibodies, and the lupus anticoagulant: significant factors associated with lupus nephritis. Ann. Rheum. Dis. 62(6), 556-560 (2003).
49. Reveille JD. Predictive value of autoantibodies for activity of systemic lupus erythematosus. Lupus 13(5), 290-297 (2004).
50. Migliorini P, Baldini C, Rocchi V, Bombardieri S. Anti-Sm and anti-RNP antibodies. Autoimmunity 38(1), 47-54 (2005).
51. Egner W. The use of laboratory tests in the diagnosis of SLE. J. Clin. Pathol. 53(6), 424-432 (2000).
52. Kurien BT, Scofield RH. Autoantibody determination in the diagnosis of systemic lupus erythematosus. Scand. J. Immunol. 64(3), 227-235 (2006).
53. Franceschini F, Cavazzana I. Anti-Ro/SSA and La/SSB antibodies. Autoimmunity 38(1), 55-63 (2005).
54. James JA, Dickey WD, Fujisaku A et al. Antigenicity of a recombinant Ro (SS-A) fusion protein. Arthritis Rheum. 33(1), 102-106 (1990).
55. Hedgpeth MT, Boulware DW Interstitial pneumonitis in antinuclear antibody-negative systemic lupus erythematosus: a new clinical manifestation and possible association with anti-Ro (SS-A) antibodies. Arthritis Rheum. 31(4), 545-548 (1988).
56. Adachi M, Mira S, Obana M, Matsuoka Y, Harada K, Irimajiri S. Thrombocytopenia subsequently develops systemic lupus erythematosus - can anti-SS-A antibody predict the next event? Jpn J. Med. 29(5), 481-486 (1990).
57. Bell DA, Smeenk RJ. Clinical connections: assays and assignment. Lupus 6(3), 305-306 (1997).
58. Harley JB, Sestak AL, Willis LG, Fu SM, Hansen JA, Reichlin M. A model for disease heterogeneity in systemic lupus erythematosus. Relationships between histocompatibility antigens, autoantibodies, and lymphopenia or renal disease. Arthritis Rheum. 32(7), 826-836 (1989).
59. Wasicek CA, Reichlin M. Clinical and serological differences between systemic lupus erythematosus patients with antibodies to Ro versus patients with antibodies to Ro and La. J. Clin. Invest. 69(4), 835-843 (1982).
60. Gomez-Puerta JA, Burlingame RW, Cervera R. Anti-chromatin (anti-nucleosome) antibodies. Lupus 15(7), 408-411 (2006).
61. Burlingame RW. The clinical utility of antihistone antibodies. Autoantibodies reactive with chromatin in systemic lupus erythematosus and drug-induced lupus. Clin. Lab. Med. 17(3), 367-378 (1997).
62. Chabre H, Amoura Z, Pierre JC, Godeau P, Bach JF, Koutouzov S. Presence of nudeosome-restricted antibodies in patients with systemic lupus erythematosus. Arthritis Rheum. 38(10), 1485-1491 (1995).
63. Cervera R, Vinas O, Ramos-Casals M et at Anti-chromatin antibodies in systemic lupus erythematosus: a useful marker for lupus nephropathy. Ann. Rheum. Dis. 62(5), 431-434 (2003).
64. Ghirardello A, Doria A, Zampieri S et al. Antinucleosome antibodies in SLE: a two-year follow-up study of 101 patients. J. Autoimmun. 22(3), 235-240 (2004).
65. Gomez-Puerta JA, Molina JF, Amaya JM, Molina J. Clinical significance of antichromatin antibodies in systemic lupus erythematosus. Lupus 10(Suppl. 1), S73 (2001).
66. Schett G, Smole J, Zimmermann C et al. The autoimmune response to chromatin antigens in systemic tupus erythematosus: autoantibodies against histone H1 are a highly specific marker for SLE associated with increased disease activity. Lupus 11(11), 704-715 (2002).
67. Simon JA, Cabiedes J, Ortiz E, Alcocer-Vareta J, Sanchez-Guerrero J. Antinucleosome antibodies in patients with systemic lupus erythematosus of recent onset. Potential utility as a diagnostic tool and disease activity marker. Rheumatology (Oxf.) 43(2), 220-224 (2004).
68. Ng KP, Manson JJ, Rahman A, Isenberg DA. Association of antinucteosome antibodies with disease flare in serologicatly active clinically quiescent patients with systemic lupus erythematosus. Arthritis Rheum. 55(6), 900-904 (2006).
69. Min DJ, Min SJ, Park SH et al. Antinucleosome antibody: significance in lupus patients lacking anti-double-stranded DNA antibody. Clin. Exp. Rheumatol. 20(1), 13-18 (2002).
70. Su Y, Jia RL, Han L, Li ZG. Role of antinucleosome antibody in the diagnosis of systemic lupus erythematosus. Clin. Immunol. 122(1), 115-120 (2007).
71. Elkon K, Skelly S, Parnassa et al. Identification and chemical synthesis of a ribosomal protein antigenic determinant in systemic lupus erythematosus. Proc. Natl Acad. Sci. USA 83(19), 7419-7423 (1986).
72. Teh LS, Lee MK, Wang F et al. Antiribosomal P protein antibodies in different populations of patients with systemic lupus erythematosus. Br. J. Rheumatol. 32(8), 663-665 (1993).
73. Teh LS, Isenberg DA. Antiribosomal P protein antibodies in systemic lupus erythematosus. A reappraisal. Arthritis Rheum. 37(3), 307-315 (1994).
74. Arnett FC, Reveille JD, Moutsopoulos HM, Georgescu L, Elkon KB. Ribosomal P autoantibodies in systemic lupus erythematosus. Frequencies in different ethnic groups and clinical and immunogenetic associations. Arthritis Rheum. 39(11), 1833-1839 (1996).
75. Eber T, Chapman J, Shoenfeld Y Antiribosomal P-protein and its role in psychiatric manifestations of systemic lupus erythematosus: myth or reality? Lupus 14(8), 571-575 (2005).
76. Bonfa E, Golombek SJ, Kaufman LD et al. Association between lupus psychosis and anti-ribosomal P protein antibodies. N. Engl. J. Med. 317(5), 265-271 (1987).
77. Schneebaum AB, Singleton JD, West SG et al. Association of psychiatric manifestations with antibodies to ribosomal P proteins in systemic lupus erythematosus. Am. J. Med. 90(1), 54-62 (1991).
78. Karassa FB, Ateltra A, Ambrozic A et al. Accuracy of anti-ribosomal P protein antibody testing for the diagnosis of neuropsychiatric systemic lupus erythematosus: an international meta-analysis. Arthritis Rheum. 54(1), 312-324 (2006).
79. do Nascimento AP, Viana Vdos S, Testagrossa Lde A et al. Antibodies to ribosomal P proteins: a potential serologic marker for lupus membranous glomerulonephritis. Arthritis Rheum. 54(5), 1568-1572 (2006).
80. Bertolaccini ML, Murru V, Alba P, Khamashta MA. Lack of association of antibodies to ribosomal P proteins with lupus membranous glomerulonephritis: comment on the article by Do Nascimento et al. Arthritis Rheum. 54(12), 4025-4026 (2006).
81. Walport MJ. Complement. First of two parts. N. Engl. J. Med. 344 (14), 1058-1066 (2001).
82. Walport MJ. Complement. Second of two parts. N. Engl. J. Med. 3440(15), 1140-1144 (2001).
83. Bowness P, Davies KA, Norsworthy PJ et al. Hereditary C1q deficiency and systemic lupus erythematosus. Q. J. Med. 87(8), 455-464 (1994).
84. Gunnarsson I, Ronnelid J, Huang YH et al. Association between ongoing anti-C1q antibody production in peripheral blood and proliferative nephritis in patients with active systemic lupus erythematosus. Br. J. Rheumatol. 36(1), 32-37 (1997).
85. Horvath L, Czirjak L, Fekete B et al. High levels of antibodies against C1q are associated with disease activity and nephritis but not with other organ manifestations in SLE patients. Clin. Exp. Rheumatol. 19(6), 667-672 (2001).
86. Seelen MA, Trouw LA, Daha MR. Diagnostic and prognostic significance of anti-C1q antibodies in systemic lupus erythematosus. Curr. Opin. Nephrol. Hypertens. 12(6), 619-624 (2003).
87. Trouw LA, Daha MR. Role of anti-C1q autoantibodies in the pathogenesis of lupus nephritis. Expert Opin. Biol. Ther. 5(2), 243-251 (2005).
88. Flierman R, Daha MR. Pathogenic role of anti-C1q autoantibodies in the development of lupus nephritis - a hypothesis. Mol. Immunol. 44(1-3), 133-138 (2007).
89. Fremeaux-Bacchi V, Noel LH, Schifferli JA. No lupus nephritis in the absence of antiC1q autoantibodies? Nephrol. Dial. Transplant. 17(12), 2041-2043 (2002).
90. Marto N, Bertolaccini ML, Calabuig E, Hughes GR, Khamashta MA. Anti-C1q antibodies in nephritis: correlation between titres and renal disease activity and positive predictive value in systemic lupus erythematosus. Ann. Rheum. Dis. 64(3), 444-448 (2005).
91. Hughes GR. Thrombosis, abortion, cerebral disease, and the lupus anticoagulant. Br. Med. J. (Clin. Res. Ed.) 287(6399), 1088-1089 (1983).
92. Wilson WA, Gharavi AE, Koike T et al. International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: report of an international workshop. Arthritis Rheum. 42(7), 1309-1311 (1999).
93. Brandt JT, Triplett DA, Alving B, Scharrer I. Criteria for the diagnosis of lupus anticoagulants: an update. On behalf of the Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibody ofthe Scientific and Standardisation Committee of the ISTH. Thromb. Haemost. 74(4), 1185-1190 (1995).
94. Cervera R, Piette JC, Font J et al. Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients. Arthritis Rheum. 46(4), 1019-1027 (2002).
95. Harris EN, Gharavi AE, Wasley GD, Hughes GR. Use of an enzyme-linked immunosorbent assay and of inhibition studies to distinguish between antibodies to cardiolipin from patients with syphilis or autoimmune disorders. J. Infect. Dis. 157(1), 23-31 (1988).
96. Galvez J, Martin I, Merino D, Pujol E. Thrombophlebitis in a patient with acute Q fever and anticardiolipin antibodies. Med. Clin. (Barc.) 108(10), 396-397 (1997).
97. Intrator L, Oksenhendler E, Desforges L, Bierling P. Anticardiolipin antibodies in HIV infected patients with or without immune thrombocytopenic purpura. Br. J. Haematol. 68(2), 269-270 (1988).
98. Love PE, Santoro SA. Antiphospholipid antibodies: anticardiolipin and the lupus anticoagulant in systemic lupus erythematosus (SLE) and in non-SLE disorders. Prevalence and clinical significance. Ann. Intern. Med. 112 (9), 682-698 (1990).
99. Ginsburg KS, Liang MH, Newcomer L et al. Anticardiolipin antibodies and the risk for ischemic stroke and venous thrombosis. Ann. Intern. Med. 117(12), 997-1002 (1992).
100. Schulman S, Svenungsson E, Granqvist S. Anticardiolipin antibodies predict early recurrence of thromboembolism and death among patients with venous thromboembolism following anticoagulant therapy. Duration of Anticoagulation Study Group. Am. J. Med. 104(4), 332-338 (1998).
101. Finazzi G, Brancaccio V, Moia M et al. Natural history and risk factors for thrombosis in 360 patients with antiphospholipid antibodies: a four-year prospective study from the Italian Registry. Am. J. Med. 100(5), 530-536 (1996).
102. Escalante A, Brey RL, Mitchell BD Jr, Dreiner U. Accuracy of anticardiolipin antibodies in identifying a history of thrombosis among patients with systemic lupus erythematosus. Am. J. Med. 98(6), 559-565 (1995).
103. Levine SR, Salowich-Palm L, Sawaya KL et al. IgG anticardiolipin antibody titer >40 GPL and the risk of subsequent thrombo-occlusive events and death. A prospective cohort study. Stroke 28(9), 1660-1665 (1997).
104. Wahl DG, Guillemin F, de Maistre E, Perret C, Lecompte T, Thibaut G. Risk for venous thrombosis related to antiphospholipid antibodies in systemic lupus erythematosus - a meta-analysis. Lupus 6(5), 467-473 (1997).
105. Wahl DG, Guillemin F, de Maistre E, Perret-Guillaume C, Lecompte T, Thibaut G. Meta-analysis of the risk of venous thrombosis in individuals with antiphospholipid antibodies without underlying autoimmune disease or previous thrombosis. Lupus 7(1), 15-22 (1998).
106. Matsuura E, Igarashi Y, Yasuda T, Triplett DA, Koike T. Anticardiolipin antibodies recognize β2-glycoprotein I structure altered by interacting with an oxygen modified solid phase surface. J. Exp. Med. 179(2), 457-462 (1994).
107. Roubey RA, Eisenberg RA, Harper MF, Winfield JB. "Anticardiolipin" autoantibodies recognize β2-glycoprotein I in the absence of phospholipid. Importance of Ag density and bivalent binding. J. Immunol. 154(2), 954-960 (1995).
108. 2-glycoprotein I in patients with antiphospholipid syndrome. Br. J. Rheumatol. 35(12), 1239-1243 (1996).
109. 2-glycoprotein-I but no antibodies detectable in standard antiphospholipid assays. Am. J. Med. 101 (5), 472-481 (1996).
110. Miyakis S, Lockshin MD, Atsumi T et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J. Thromb. Haemost. 4(2), 295-306 (2006).
111. Galli M, Luciani D, Bertolini G, Barbui T. Anti-β2-glycoprotein I, antiprothrombin antibodies, and the risk of thrombosis in the antiphospholipid syndrome. Blood 102(8), 2717-2723 (2003).
112. Bertolaccini ML, Atsumi T, Koike T, Hughes GR, Khamashta MA. Antiprothrombin antibodies detected in two different assay systems. Prevalence and clinical significance in systemic lupus erythematosus. Thromb. Haemost. 9(2), 289-297 (2005).
113. Bertolaccini ML, Gomez S, Pareja JF et al. Antiphospholipid antibody tests: spreading the net. Ann. Rheum. Dis. 64(11), 1639-1643 (2005).